Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 1,2,3,4-tetrahydro-9-acridinamine
2. 1,2,3,4-tetrahydroaminoacridine
3. 9-amino-1,2,3,4-tetrahydroacridine
4. Cognex
5. Romotal
6. Tacrine
7. Tenakrin
8. Tetrahydroaminoacridine
9. Tha
1. 1684-40-8
2. Tacrine Hcl
3. 1,2,3,4-tetrahydroacridin-9-amine Hydrochloride
4. Cognex
5. Hydroaminacrine
6. 9-amino-1,2,3,4-tetrahydroacridine Hydrochloride
7. Romotal
8. Tenakrin
9. Ci-970
10. Tacrine.hcl
11. Tacrine (hydrochloride)
12. 9-acridinamine, 1,2,3,4-tetrahydro-, Monohydrochloride
13. Nsc-72108
14. 1,2,3,4-tetrahydro-9-acridinamine Hydrochloride
15. Mls000028845
16. 4966rng0bu
17. 9-acridinamine, 1,2,3,4-tetrahydro-, Hydrochloride (1:1)
18. 1,2,3,4-tetrahydro-9-aminoacridine Hydrochloride
19. 9-amino-1,2,3,4-tetrahydroacridine Monohydrochloride
20. 9-amino-1,2,3,4-tetrahydroacridine Hydrochloride Dihydrate
21. Smr000059105
22. 1,2,3,4-tetrahydroacridin-9-amine;hydrochloride
23. 1,2,3,4-tetrahydro-9-acridinamine Monohydrochloride
24. Sr-01000075593
25. Cas-1684-40-8
26. Unii-4966rng0bu
27. Tacrine Hydrochloride [usan]
28. Ccris 7250
29. T.h.a.
30. Oros-tacrine
31. Tacrine Hydrochloride [usan:usp]
32. Tacrine Hydrochlorid
33. Tacrin Hydrochloride
34. Einecs 216-867-5
35. 1,2,3,4-tetrahydroacridin-9-amine Monohydrochloride
36. Ci 970
37. Cognex (tn)
38. Nsc 72108
39. Tha.hcl
40. Cpd000059105
41. Opera_id_296
42. Dsstox_cid_6112
43. Schembl3270
44. 1,2,3,4-tetrahydroacridin-9-aminehydrochloride
45. Chembl1677
46. Dsstox_rid_78021
47. Dsstox_gsid_26112
48. Tacrine Hydrochloride (usp)
49. Mls000758202
50. Mls001401372
51. Spectrum2300104
52. Acridine, 9-amino-1,2,3,4-tetrahydro-, Hydrochloride
53. Dtxsid1026112
54. Acridine, 9-amino-1,2,3,4-tetrahydro-, Monohydrochloride
55. Ci970
56. Pharmakon1600-02300104
57. Tacrine Hydrochloride [mi]
58. Act08745
59. Amy10870
60. Bcp29701
61. Hy-b1488
62. Nsc72108
63. Tox21_200299
64. Tox21_500036
65. Ccg-39606
66. Mfcd00012657
67. Nsc759324
68. S4357
69. Tacrine Hydrochloride [vandf]
70. Tacrine Hydrochloride [mart.]
71. Akos015913476
72. Tacrine Hydrochloride [who-dd]
73. Lp00036
74. Nc00068
75. Nsc-759324
76. Tacrine Hydrochloride; Tha Hydrochloride
77. Tetrahydroaminoacridine Monohydrochloride
78. Ncgc00024908-02
79. Ncgc00093554-01
80. Ncgc00093554-02
81. Ncgc00093554-03
82. Ncgc00093554-04
83. Ncgc00257853-01
84. Ncgc00260721-01
85. 1,2,3,4-tetrahydroacridin-9-amine Hcl
86. Ds-16390
87. Tacrine Hydrochloride [orange Book]
88. Db-043738
89. Tacrine Hydrochloride [usp Impurity]
90. B6527
91. Cs-0013186
92. Eu-0100036
93. Ft-0633768
94. Sw033163-6
95. A 3773
96. Acridine,2,3,4-tetrahydro-, Monohydrochloride
97. D02068
98. F20766
99. A810973
100. J-010457
101. Sr-01000075593-1
102. Sr-01000075593-3
103. Sr-01000075593-9
104. 9-acridinamine,2,3,4,-tetrahydro-, Monohydrochloride
105. Q27259239
106. Sr-01000075593-16
107. Acridine, 1,2,3,4-tetrahydro-9-amino-, Monohydrochloride
108. Tacrine Hcl;hydroaminacrine; Nsc72108; Nsc-72108; Nsc72108
Molecular Weight | 234.72 g/mol |
---|---|
Molecular Formula | C13H15ClN2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 234.0923762 g/mol |
Monoisotopic Mass | 234.0923762 g/mol |
Topological Polar Surface Area | 38.9 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 229 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
Nootropic Agents
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
ABOUT THIS PAGE
10
PharmaCompass offers a list of Tacrine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tacrine manufacturer or Tacrine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tacrine manufacturer or Tacrine supplier.
PharmaCompass also assists you with knowing the Tacrine API Price utilized in the formulation of products. Tacrine API Price is not always fixed or binding as the Tacrine Price is obtained through a variety of data sources. The Tacrine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A NCGC00024908-02 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NCGC00024908-02, including repackagers and relabelers. The FDA regulates NCGC00024908-02 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NCGC00024908-02 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of NCGC00024908-02 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A NCGC00024908-02 supplier is an individual or a company that provides NCGC00024908-02 active pharmaceutical ingredient (API) or NCGC00024908-02 finished formulations upon request. The NCGC00024908-02 suppliers may include NCGC00024908-02 API manufacturers, exporters, distributors and traders.
click here to find a list of NCGC00024908-02 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A NCGC00024908-02 DMF (Drug Master File) is a document detailing the whole manufacturing process of NCGC00024908-02 active pharmaceutical ingredient (API) in detail. Different forms of NCGC00024908-02 DMFs exist exist since differing nations have different regulations, such as NCGC00024908-02 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A NCGC00024908-02 DMF submitted to regulatory agencies in the US is known as a USDMF. NCGC00024908-02 USDMF includes data on NCGC00024908-02's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The NCGC00024908-02 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of NCGC00024908-02 suppliers with USDMF on PharmaCompass.
NCGC00024908-02 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NCGC00024908-02 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right NCGC00024908-02 GMP manufacturer or NCGC00024908-02 GMP API supplier for your needs.
A NCGC00024908-02 CoA (Certificate of Analysis) is a formal document that attests to NCGC00024908-02's compliance with NCGC00024908-02 specifications and serves as a tool for batch-level quality control.
NCGC00024908-02 CoA mostly includes findings from lab analyses of a specific batch. For each NCGC00024908-02 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NCGC00024908-02 may be tested according to a variety of international standards, such as European Pharmacopoeia (NCGC00024908-02 EP), NCGC00024908-02 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NCGC00024908-02 USP).